Table of Content

Open Access iconOpen Access

ARTICLE

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer

John B. Malcolm1, Ithaar H. Derweesh1, Matthew C. Kincade1, Christopher J. DiBlasio1, Kimberly D. Lamar2, Robert W. Wake1, Anthony L. Patterson1

1 Department of Urology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
2 Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA
Address correspondence to Dr. Ithaar H. Derweesh, Department of Urology, University of Tennessee Health Science Center, 956 Court Avenue, Room H210, Memphis, TN 38163 USA

Canadian Journal of Urology 2007, 14(3), 3551-3559.

Abstract

Introduction: Androgen deprivation therapy (ADT) is widely utilized for treatment of localized and advanced prostate cancer (CaP). ADT is associated with increased rates of osteoporosis; however, its impact on fracture risk is not completely understood. We investigated incidence and predisposing factors for osteoporosis and fractures in a large, contemporary, single institution series of patients treated with ADT for CaP.
Methods: We retrospectively reviewed medical records of all patients who received ADT for CaP between 1/1989 and 7/2005. Primary endpoints of investigation were osteoporosis and non-pathologic fractures. Independent variables included age, race, body mass index (BMI), pretreatment serum PSA, Gleason sum, clinical stage, ADT type (medical versus surgical) and schedule (continuous versus intermittent), and receipt of calcium, vitamin D or bisphosphonate supplementation. Data were analyzed by Chi-square test, Student's t-test, Linear Regression, and Logistic Regression (p < 0.05 significant).
Results: A total of 395 patients were analyzed (mean age 71.7 years, 59% African American, 41% Caucasian/other). At mean follow-up of 66.1 months, 92 (23%) patients developed osteoporosis and 27 (7%) patients developed non-pathologic fractures. On univariate analysis, age, race, BMI, and ADT duration were significantly associated with osteoporosis development, while BMI, ADT duration, and presence of osteoporosis were significantly associated with fracture incidence. Regression analysis revealed that age >70 at ADT initiation, continuous ADT, and increased treatment duration predicted osteoporosis development, while only osteoporosis was independently predictive of fracture development.
Conclusions: Patients receiving continuous ADT for CaP are at increased risk for developing osteoporosis which may lead to fractures, with an incidence of 7% in our study population.

Keywords

prostate cancer, androgen deprivation therapy, hormonal therapy, complications, fractures, osteoporosis

Cite This Article

APA Style
Malcolm, J.B., Derweesh, I.H., Kincade, M.C., DiBlasio, C.J., Lamar, K.D. et al. (2007). Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Canadian Journal of Urology, 14(3), 3551–3559.
Vancouver Style
Malcolm JB, Derweesh IH, Kincade MC, DiBlasio CJ, Lamar KD, Wake RW, et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urology. 2007;14(3):3551–3559.
IEEE Style
J.B. Malcolm et al., “Osteoporosis and fractures after androgen deprivation initiation for prostate cancer,” Can. J. Urology, vol. 14, no. 3, pp. 3551–3559, 2007.



cc Copyright © 2007 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 113

    View

  • 96

    Download

  • 0

    Like

Share Link